| Average Daily Range |
| Avg Daily Range: |
$0.25 | 4.50%
|
| Avg Daily Range (30 D): |
$0.39 | 4.77%
|
| Avg Daily Range (90 D): |
$0.33 | 5.40%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
5.51M |
| Avg Daily Volume (30 D): |
24.25M |
| Avg Daily Volume (90 D): |
29.04M |
| Trade Size |
| Avg Trade Size (Sh.): |
252 |
| Avg Trade Size (Sh.) (30 D): |
279 |
| Avg Trade Size (Sh.) (90 D): |
321 |
| Institutional Trades |
| Total Institutional Trades: |
1,857 |
| Avg Institutional Trade: |
$1.85M |
| Avg Institutional Trade (30 D): |
$2.06M |
| Avg Institutional Trade (90 D): |
$1.86M |
| Avg Institutional Trade Volume: |
.36M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$6.91M |
| Avg Closing Trade (90 D): |
$5.11M |
| Avg Closing Volume: |
423.05K |
|
|
| News |
Apr 10, 2026 @ 10:48 PM
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestiv...
Source: Rosen Law Firm
|
Apr 10, 2026 @ 10:45 PM
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Invest...
Source: Hagens Berman
|
Apr 10, 2026 @ 10:31 PM
FBRT DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUN...
Source: Rosen Law Firm
|
Apr 10, 2026 @ 9:43 PM
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityB...
Source: Rosen Law Firm
|
Apr 10, 2026 @ 2:51 PM
IBRX Investors Have Opportunity to Lead ImmunityBi...
Source: The Schall Law Firm
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-.38
|
$-.06
|
$-.38
|
|
Diluted EPS
|
$-.38
|
$-.06
|
$-.38
|
|
Revenue
|
$113.29M
|
$38.29M
|
$113.29M
|
|
Gross Profit
|
$112.54M
|
$37.9M
|
$112.54M
|
|
Net Income / Loss
|
$-351.47M
|
$-61.96M
|
$-351.47M
|
|
Operating Income / Loss
|
$-256.03M
|
$-64.68M
|
$-256.03M
|
|
Cost of Revenue
|
$.75M
|
$.38M
|
$.75M
|
|
Net Cash Flow
|
$-54.5M
|
$28.09M
|
$-54.5M
|
|
PE Ratio
|
|
|
|
|
|
|
